Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme

After median follow up of 3.9 years, UK RCT (n= 1694) found no evidence of a difference in time to first cardiovascular event between luteinising hormone releasing hormone agonists or transdermal oestradiol patches (HR. 1.11, 95% CI 0.80–1.53; p=0.54).

Source:

The Lancet